Alteration of the intestinal microbiota as a cause of and a potential therapeutic option in irritable bowel syndrome
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The intestinal microbiota forms a complex ecosystem that is in close contact with its host and has an important impact on health. An increasing number of disorders are associated with disturbances in this ecosystem. Also patients suffering from irritable bowel syndrome (IBS) show an altered composition of their gut microbiota. IBS is a multifactorial chronic disorder characterised by various abdominal complaints and a worldwide prevalence of 10-20%. Even though its aetiology and pathophysiology are complex and not well understood, it is widely accepted that aberrations along the microbe-gut-brain axis are involved. In this review, it will be discussed how exogenous factors, e.g. antibiotics, can cause disbalance in the intestinal microbiota and thereby contribute to the development of IBS. In addition, several new IBS treatment options that aim at re-establishing a healthy, beneficial ecosystem will be described. These include antibiotics, probiotics, prebiotics and faecal transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Composition, variability, and temporal stability of the intestinal microbiota of the elderly
Claesson, M. J., Cusack, S., O'Sullivan, O., Greene-Diniz, R., de Weerd, H., Flannery, E., Marchesi, J. R., Falush, D., Dinan, T., Fitzgerald, G., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000097107 · Cited by 1,754
Le Poul, E., Loison, C., Struyf, S., Springael, J.-Y., Lannoy, V., Decobecq, M.-E., Brezillon, S., Dupriez, V., Vassart, G., Van Damme, J., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301403200 · Cited by 1,651
The burden of selected digestive diseases in the United States
Sandler, R. S., Everhart, J. E., Donowitz, M., Adams, E., Cronin, K., Goodman, C., Gemmen, E., Shah, S., Avdic, A., & Rubin, R. (2002) · Gastroenterology · doi:10.1053/gast.2002.32978 · Cited by 1,512
O’Mahony, L., McCarthy, J., Kelly, P., Hurley, G., Luo, F., Chen, K., O’Sullivan, G. C., Kiely, B., Collins, J. K., Shanahan, F., et al. (2005) · Gastroenterology · doi:10.1053/j.gastro.2004.11.050 · Cited by 1,448
Rajilić–Stojanović, M., Biagi, E., Heilig, H. G. H. J., Kajander, K., Kekkonen, R. A., Tims, S., & de Vos, W. M. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.043 · Cited by 1,041
Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation
Pimentel, M., Lembo, A., Chey, W. D., Zakko, S., Ringel, Y., Yu, J., Mareya, S. M., Shaw, A. L., Bortey, E., & Forbes, W. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1004409 · Cited by 1,036 · cited 2×
“In addition, rifaximin was effective in retreating patients that presented with a relapse after the first antibiotic treatment, and it does not seem to provoke clinical resistance (Pimentel et al. , 2011b; Yang et al. , 2008).”
Kassinen, A., Krogius-Kurikka, L., Mäkivuokko, H., Rinttilä, T., Paulin, L., Corander, J., Malinen, E., Apajalahti, J., & Palva, A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.005 · Cited by 1,002 · cited 3×
“A follow-up study of only the diarrhoea-predominant IBS subtype (n=10) found high numbers of Proteobacteria and Firmicutes and low numbers of Actinobacteria and Bacteroidetes compared to controls (Krogius-Kurikka et al. , 2009).”
Intestinal microbiota in functional bowel disorders: a Rome foundation report
Simrén, M., Barbara, G., Flint, H. J., Spiegel, B. M. R., Spiller, R. C., Vanner, S., Verdu, E. F., Whorwell, P. J., & Zoetendal, E. G. (2013) · Gut · doi:10.1136/gutjnl-2012-302167 · Cited by 939 · cited 3×
“Some strains have been shown to improve total symptom scores in IBS patients, while others primarily seem to affect bloating and flatulence or stool frequency (Simren et al. , 2013).”
InfluentialSwidsinski, A., Weber, J., Loening-Baucke, V., Hale, L. P., & Lochs, H. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3380-3389.2005 · Cited by 894 · cited 1×
“An earlier study using fluorescence in situ hybridisation also reported a higher number of mucosal bacteria in IBS patients (Swidsinski et al. , 2005).”
McFarland, L. V. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00465.x · Cited by 872 · cited 1×
“Strong evidence for the effectiveness of probiotics has been demonstrated regarding the treatment of antibiotic-associated traveller’s and paediatric diarrhoea (McFarland, 2006, 2007; Szajewska et al. , 2006).”
Zoetendal, E. G., von Wright, A., Vilpponen-Salmela, T., Ben-Amor, K., Akkermans, A. D. L., & de Vos, W. M. (2002) · Applied and Environmental Microbiology · doi:10.1128/aem.68.7.3401-3407.2002 · Cited by 868 · cited 2×
“Studies have shown that the mucosa-adherent microbiota differ significantly from the faecal one (Carroll et al. , 2011; Eckburg et al. , 2005; Zoetendal et al. , 2002).”
Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C., & Gahan, C. G. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700440104 · Cited by 853
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota
Jeffery, I. B., O'Toole, P. W., Öhman, L., Claesson, M. J., Deane, J., Quigley, E. M. M., & Simrén, M. (2012) · Gut · doi:10.1136/gutjnl-2011-301501 · Cited by 835 · cited 3×
“This ratio was also found to be increased in a recent study using pyrosequencing of 16S rRNA (Jeffery et al. , 2012).”
Activation of the mucosal immune system in irritable bowel syndrome
Chadwick, V. S., Chen, W., Shu, D., Paulus, B., Bethwaite, P., Tie, A., & Wilson, I. (2002) · Gastroenterology · doi:10.1053/gast.2002.33579 · Cited by 833 · cited 1×
“Mild immune activation has been found both locally in the gut and systemically (Barbara et al. , 2011), and mucosal biopsies from IBS patients are characterised by an increased quantity of various immune cells, such as mast cells (Bischoff, 2009; Chadwick et al. , 2002; Cremon et al. , 2009).”
Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors
Rousseaux, C., Thuru, X., Gelot, A., Barnich, N., Neut, C., Dubuquoy, L., Dubuquoy, C., Merour, E., Geboes, K., Chamaillard, M., et al. (2007) · Nature Medicine · doi:10.1038/nm1521 · Cited by 793 · cited 1×
“By inducing the expression of opioid and cannabinoid receptors, some probiotics might also be able to modulate the perception of visceral pain (Rousseaux et al. , 2007).”
Malinen, E., Rinttila, T., Kajander, K., Matto, J., Kassinen, A., Krogius, L., Saarela, M., Korpela, R., & Palva, A. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.40312.x · Cited by 699 · cited 2×
“…et al. , 2006) and the so-called ‘Finnish combination’ consisting of Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp . shermanii JS and Bifidobacterium breve Bb99 or Bifidobacterium animalis ssp . lactis Bb12, respectively (Kajander et al. , 2005, 2008).”
An Evidence-Based Position Statement on the Management of Irritable Bowel Syndrome
American College of Gastroenterology IBS Task Force (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.122 · Cited by 694
Fecal microbiota transplantation and emerging applications
Borody, T. J., & Khoruts, A. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2011.244 · Cited by 677
Karczewski, J., Troost, F. J., Konings, I., Dekker, J., Kleerebezem, M., Brummer, R.-J. M., & Wells, J. M. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00327.2009 · Cited by 676 · cited 2×
“In addition, probiotics are able to enhance epithelial barrier function by activating signalling pathways that lead to increased expression of tight junction proteins or enhanced mucus production (Karczewski et al. , 2010; Spiller, 2008).”
Brandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“In this disorder, faecal transplantation has a cure rate of over 90% (Gough et al. , 2011), and has been proven to be a durable and safe method according to a recent multicentre long-term follow-up study (Brandt et al. , 2012).”
Should we standardize the 1,700-year-old fecal microbiota transplantation?
Zhang, F., Luo, W., Shi, Y., Fan, Z., & Ji, G. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.251 · Cited by 619
SILK, D. B. A., DAVIS, A., VULEVIC, J., TZORTZIS, G., & GIBSON, G. R. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03911.x · Cited by 551
THE MICROBIAL CONTRIBUTION TO HUMAN FAECAL MASS
Stephen, A. M., & Cummings, J. H. (1980) · Journal of Medical Microbiology · doi:10.1099/00222615-13-1-45 · Cited by 545 · cited 1×
“The microorganisms in human faeces account for about 50% of the dry matter, which otherwise consists mostly of fibres and soluble material, as analysed in healthy subjects on a British-type diet (Stephen and Cummings, 1980).”
Small intestinal bacterial overgrowth in patients with irritable bowel syndrome
Posserud, I., Stotzer, P.-O., Björnsson, E. S., Abrahamsson, H., & Simrén, M. (2007) · Gut · doi:10.1136/gut.2006.108712 · Cited by 499 · cited 1×
“However, the use of LBT to diagnose SIBO is controversial, and several other studies did not find any association between IBS and SIBO (Ford et al. , 2009; Posserud et al. , 2007).”
Rajilić‐Stojanović, M., Heilig, H. G. H. J., Molenaar, D., Kajander, K., Surakka, A., Smidt, H., & De Vos, W. M. (2009) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.01900.x · Cited by 484
Carroll, I. M., Ringel‐Kulka, T., Siddle, J. P., & Ringel, Y. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2012.01891.x · Cited by 425 · cited 1×
“However, results described in literature are inconsistent, and both a loss of diversity (Carroll et al. , 2012; Codling et al. , 2010) as well as an increased heterogeneity have been reported (Rajilic-Stojanovic, 2007).”
Butyrate modulates oxidative stress in the colonic mucosa of healthy humans
Hamer, H. M., Jonkers, D. M. A. E., Bast, A., Vanhoutvin, S. A. L. W., Fischer, M. A. J. G., Kodde, A., Troost, F. J., Venema, K., & Brummer, R.-J. M. (2009) · Clinical Nutrition · doi:10.1016/j.clnu.2008.11.002 · Cited by 400
Self-citationKAJANDER, K., MYLLYLUOMA, E., RAJILIĆ‐STOJANOVIĆ, M., KYRÖNPALO, S., RASMUSSEN, M., JÄRVENPÄÄ, S., ZOETENDAL, E. G., DE VOS, W. M., VAPAATALO, H., & KORPELA, R. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03542.x · Cited by 367
KAJANDER, K., HATAKKA, K., POUSSA, T., FÄRKKILÄ, M., & KORPELA, R. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02579.x · Cited by 361
Ford, A. C., Spiegel, B. M. R., Talley, N. J., & Moayyedi, P. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.06.031 · Cited by 351
Cremon, C., Gargano, L., Morselli-Labate, A. M., Santini, D., Cogliandro, R. F., De Giorgio, R., Stanghellini, V., Corinaldesi, R., & Barbara, G. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.94 · Cited by 342 · cited 1×
“Mild immune activation has been found both locally in the gut and systemically (Barbara et al. , 2011), and mucosal biopsies from IBS patients are characterised by an increased quantity of various immune cells, such as mast cells (Bischoff, 2009; Chadwick et al. , 2002; Cremon et al. , 2009).”
Meta-analysis of probiotics for the treatment of irritable bowel syndrome
McFarland, L. V., & Dublin, S. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2650 · Cited by 341
Fecal microbiota transplantation: past, present and future
Aroniadis, O. C., & Brandt, L. J. (2013) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e32835a4b3e · Cited by 336 · cited 1×
“…faecal transplantation has also been reported in other disorders, including inflammatory bowel disease, multiple sclerosis, autism, and chronic fatigue syndrome, mainly reflecting case studies (Aroniadis and Brandt, 2013; Borody and Campbell, 2012; Borody and Khoruts, 2011; Borody et al. , 2003).”
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N., & Glasziou, P. (2009) · BMC Gastroenterology · doi:10.1186/1471-230x-9-15 · Cited by 297 · cited 1×
“Several meta-analyses came to the conclusion that probiotic use improves IBS symptoms and might be a promising treatment option (Hoveyda et al. , 2009; McFarland and Dublin, 2008; Nikfar et al. , 2008).”
Kerckhoffs, A. P., Samsom, M., Rest, M. E. V. D., Vogel, J. D., Knol, J., Ben-Amor, K., & Akkermans, L. M. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.2887 · Cited by 289 · cited 1×
“Kerckhoffs et al. (2009) used real-time PCR to analyse the composition of bifidobacteria in faecal and duodenal mucosa brush samples of IBS patients, and found lower values of B. catenulatum compared to controls.”
Menees, S. B., Maneerattannaporn, M., Kim, H. M., & Chey, W. D. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.355 · Cited by 283 · cited 1×
“These results are supported by a meta-analysis that included five studies and found improvement of IBS symptoms using rifaximin with a modest therapeutic gain similar to other currently available IBS therapies (Menees et al. , 2012).”
Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives
Salonen, A., de Vos, W. M., & Palva, A. (2010) · Microbiology · doi:10.1099/mic.0.043257-0 · Cited by 264 · cited 2×
“It is now widely accepted that a disbalanced gut ecosystem also plays an important role in the pathophysiology of IBS (Salonen et al. , 2010).”
A Molecular Analysis of Fecal and Mucosal Bacterial Communities in Irritable Bowel Syndrome
Codling, C., O’Mahony, L., Shanahan, F., Quigley, E. M. M., & Marchesi, J. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-0934-x · Cited by 243
Borody, T. J., George, L., Andrews, P., Brandl, S., Noonan, S., Cole, P., Hyland, L., Morgan, A., Maysey, J., & Moore‐Jones, D. (1989) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1989.tb136704.x · Cited by 221
The immune system in irritable bowel syndrome
Barbara, G., Cremon, C., Carini, G., Bellacosa, L., Zecchi, L., Giorgio, R. D., Corinaldesi, R., & Stanghellini, V. (2011) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm.2011.17.4.349 · Cited by 211 · cited 1×
“Mild immune activation has been found both locally in the gut and systemically (Barbara et al. , 2011), and mucosal biopsies from IBS patients are characterised by an increased quantity of various immune cells, such as mast cells (Bischoff, 2009; Chadwick et al. , 2002; Cremon et al. , 2009).”
Parkes, G. C., Rayment, N. B., Hudspith, B. N., Petrovska, L., Lomer, M. C., Brostoff, J., Whelan, K., & Sanderson, J. D. (2012) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2011.01803.x · Cited by 200
Drakoularakou, A., Tzortzis, G., Rastall, R. A., & Gibson, G. R. (2010) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2009.120 · Cited by 174 · cited 1×
“In adults, suggested health benefits of prebiotics include protection against traveller’s and antibiotic-associated diarrhoea (Drakoularakou et al. , 2010; Lewis et al. , 2005).”
The effects of butyrate enemas on visceral perception in healthy volunteers
Vanhoutvin, S. A. L. W., Troost, F. J., Kilkens, T. O. C., Lindsey, P. J., Hamer, H. M., Jonkers, D. M. A. E., Venema, K., & Brummer, R. ‐. M. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01324.x · Cited by 171
Self-citationLyra, A., Rinttilä, T., Nikkilä, J., Krogius-Kurikka, L., Kajander, K., Malinen, E., Mättö, J., Mäkelä, L., & Palva, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5936 · Cited by 160 · cited 1×
“In a further study, this group applied additional qPCR assays to samples classified according to IBS subgroups (Lyra et al. , 2009).”
Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials
Nikfar, S., Rahimi, R., Rahimi, F., Derakhshani, S., & Abdollahi, M. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9335-z · Cited by 155
Yang, J., Lee, H.-R., Low, K., Chatterjee, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9839-8 · Cited by 129
TSUCHIYA, J., BARRETO, R., OKURA, R., KAWAKITA, S., FESCE, E., & MAROTTA, F. (2004) · Chinese Journal of Digestive Diseases · doi:10.1111/j.1443-9573.2004.00176.x · Cited by 108 · cited 1×
“It included 68 IBS patients and reported improvement of abdominal pain and bowel habits using a novel synbiotic known as SCM-III, and successfully increased lactobacilli, eubacteria and bifididobacteria (Tsuchiya et al. , 2004).”
Ligaarden, S. C., Axelsson, L., Naterstad, K., Lydersen, S., & Farup, P. G. (2010) · BMC Gastroenterology · doi:10.1186/1471-230x-10-16 · Cited by 103
KAJANDER, K., KROGIUS‐KURIKKA, L., RINTTILÄ, T., KARJALAINEN, H., PALVA, A., & KORPELA, R. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03391.x · Cited by 95
Andrews, P. J., & Borody, T. J. (1993) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1993.tb138063.x · Cited by 48 · cited 1×
“The same group applied a mixture of 18 cultured, non-pathogenic bacteria resembling normal gut microbiota into the caecum of IBS patients and reported improved symptoms in 25 out of 33 (Andrews and Borody, 1993).”
Cited by
Human Intestinal Barrier Function in Health and Disease
König, J., Wells, J., Cani, P. D., García-Ródenas, C. L., MacDonald, T., Mercenier, A., Whyte, J., Troost, F., & Brummer, R.-J. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2016.54 · Cited by 780
Self-citationCan probiotics modulate human disease by impacting intestinal barrier function?
Bron, P. A., Kleerebezem, M., Brummer, R.-J., Cani, P. D., Mercenier, A., MacDonald, T. T., Garcia-Ródenas, C. L., & Wells, J. M. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114516004037 · Cited by 499
“Overall, the results of these trials are difficult to interpret, because of the use of different strains and combinations thereof, as well as limitations in the study designs((186)).”
BackgroundThe role of the microbiome for human health: From basic science to clinical applications
Mohajeri, M. H., Brummer, R. J. M., Rastall, R. A., Weersma, R. K., Harmsen, H. J. M., Faas, M., & Eggersdorfer, M. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1703-4 · Cited by 440
“The human gut microbiota consists of trillions of microbes which form a complex ecosystem [35].”
BackgroundInfluentialSelf-citationGut microbiota role in irritable bowel syndrome: New therapeutic strategies
Distrutti, E., Monaldi, L., Ricci, P., & Fiorucci, S. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i7.2219 · Cited by 320
Hydrogen sulfide in physiology and diseases of the digestive tract
Singh, S., & Lin, H. (2015) · Microorganisms · doi:10.3390/microorganisms3040866 · Cited by 260
Metadata
- Authors
- König, J., & Brummer, R. J.
- Venue
- Beneficial Microbes
- Publisher
- Walter de Gruyter GmbH
- Published
- 2014-09-01
- Volume
- 5
- Issue
- 3
- Pages
- 247-262
- ISSN
- 1876-2883 (ISSN-L)
- 1876-2891
- OpenAlex
- W2069506614
- Cited by
- 42
- References
- 50
- FWCI
- 7.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.